In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

For patients with diabetes, a systolic target of 120 mm Hg led to a significant reduction in CV events in BPROADS, mirroring ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

As a new study finds that people who stopped taking semaglutide, the active ingredient in the new blockbuster weight loss ...

Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...